Global trust in pharma CEOs in the doldrums when it comes to ‘telling the truth about health’news2022-04-22T11:49:09+00:00April 22nd, 2022|Fierce Pharma|
With millions on the line, Alkermes, J&J start arbitration over drug delivery tech disputenews2022-04-22T09:58:56+00:00April 22nd, 2022|Fierce Pharma|
Consegna buys Fathom to expand long-acting injectable pipelinenews2022-04-22T09:55:39+00:00April 22nd, 2022|Fierce Pharma|
BioMarin joins pharma’s filmmaking push with hemophilia documentary projectnews2022-04-22T09:43:05+00:00April 22nd, 2022|Fierce Pharma|
Apellis, nearing FDA filing for its eye drug, starts early awareness pushnews2022-04-22T07:56:18+00:00April 22nd, 2022|Fierce Pharma|
‘Betrayal of public trust’: Pfizer under fire for resisting Paxlovid compulsory licensenews2022-04-21T18:40:57+00:00April 21st, 2022|Fierce Pharma|
Fast-growing Catalent plots $350M expansion and 1,000 new hires in USnews2022-04-21T17:08:55+00:00April 21st, 2022|Fierce Pharma|
COVID-19 vaccine sales slumping now, but analysts optimistic about rebound later this yearnews2022-04-21T16:01:33+00:00April 21st, 2022|Fierce Pharma|
In Repatha patent feud, Supreme Court asks United States’ top lawyer to weigh Amgen’s appealnews2022-04-21T14:14:06+00:00April 21st, 2022|Fierce Pharma|
Biogen brings an unlikely lobbyist into its Alzheimer’s corner. Could a CMS challenge follow?news2022-04-21T14:12:43+00:00April 21st, 2022|Fierce Pharma|
